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Abstract (200 words max.): 
 
Purpose of review: Epithelial neutral amino acid transporters have been identified at the 
molecular level in recent years. Mouse models have now established the crucial role of these 
transporters for systemic amino acid homeostasis. The review summarises recent progress in 
this field. 
 
Recent findings: Epithelial neutral amino acid transporters play an important role in the 
homeostasis of neutral amino acid levels in the body. They are important for the 
maintenance of body weight, muscle mass and serve as fuels. They also serve a role in 
providing nutrients to epithelial cells. Changes of plasma amino acid levels are not 
necessarily correlated to the amino acids appearing in the urine, changes to organ amino 
acid metabolism need to be taken into account. 
 
Summary: Genetic deletion of neutral amino acid transporters provides insight into their role 
in protein nutrition and homestasis. 
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Introduction 
The majority of epithelial amino acid transporters have been identified in recent years [1-3]. 
Many of these are expressed in both intestinal and renal epithelia (Fig. 1,2). Following their 
molecular characterisation a more systemic analysis is now achieved through the generation 
of mouse models. This review will focus on insights provided by mouse models of epithelial 
transporters in recent years. 
Molecular and cellular organisation of amino acid uptake in the kidney and intestine 
The bulk of neutral amino acid uptake in both kidney and intestine is mediated by the amino 
acid transporter B0AT1 (SLC6A19), which accepts a broad (B) variety of neutral (0) amino 
acids [4]. Mutations in B0AT1 (SLC6A19) cause Hartnup disorder, a rare inherited condition 
that is characterised by highly elevated amounts of neutral amino acids in the urine [5-7]. 
B0AT1 is mainly expressed in the kidney and intestine, lower expression levels are found in 
the skin and pancreas. B0AT1 expression at the apical cell surface requires coexpression of 
the single-pass membrane proteins collectrin (TMEM27) in the kidney [8] or angiotensin-
converting enzyme 2 (ACE2) in the intestine [9,10]. B0AT1 is highly expressed in the early 
segments of the proximal tubule (mainly S1), while collectrin is found along the entire 
proximal tubule [11,12]. The accessory protein does not seem to influence the transport 
activity, but some B0AT1 mutations appear to interact slightly differently with ACE2 and 
collectrin [9]. A differential interaction of B0AT1 mutations with ACE2 and collectrin may 
explain rare cases of purely renal [13,14] or purely intestinal [15] Hartnup disorder. 
Transport activity of B0AT1 is affected by the presence of Aminopeptidase N, which forms 
larger complexes with B0AT1 and ACE2 generating transport metabolomes that optimise 
peptide digestion and transport [16].  
Proline and glycine have additional transporters in both kidney and intestine (Fig. 1) and 
species differences have to be taken into account to avoid confusion (reviewed in [17]). In 
mice, renal glycine uptake is largely mediated by B0AT3 (SLC6A18), which also contributes to 
the reabsorption of other neutral amino acids [12]. B0AT3 is mainly expressed in the apical 
membrane of epithelial cells in the S3 segment of the proximal tubule. Like B0AT1 it requires 
coexpression of ACE2 or collectrin to reach the cell surface [11]. The physiological partner is 
collectrin, which has overlapping expression with B0AT3 [11,12]. The transporter prefers 
short neutral amino acids such as glycine and alanine. Renal proline uptake is mediated by 
SIT1 (SLC6A20) in mouse and humans [11]. B0AT3 appears to be inactive in humans and is 
replaced by the proton amino acid transporter PAT2 (SLC36A2), which transports both 
glycine and proline [18]. Mutations in PAT2 cause iminoglycinuria, a benign condition, 
characterised by the spillover of glycine and proline into the urine [18]. SIT1 mutations have 
a modifying effect on the urinary profile. In the intestine proline and glycine uptake is 
mediated by the proton amino acid transporter PAT1 in both mice and humans [19]. Release 
of neutral amino acids through the basolateral membrane is not fully understood. The 
heteromeric amino acid transporter 4F2hc/LAT2 (SLC3A2/SLC7A8) is localised in the 
basolateral membrane and accepts all neutral amino acids [20-22]. However, the 
transporter is an obligatory antiporter and thus cannot mediate net efflux of bulk amounts 
of neutral amino acids. The transporter is comprised of two subunits, the 4F2 heavy chain 
and LAT2 light chain, which are linked by a disulphide bridge. For aromatic amino acids a 
specific transporter, TAT1 (SLC16A10), has been identified in the basolateral membrane of 
both kidney and intestine [23]. TAT1 is found in the early segments of the proximal tubule 
(S1 and S2) and is colocalised with LAT2 [24]. TAT1 can mediate net efflux of aromatic amino 
acids across the basolateral membrane. The major net efflux transporter for neutral amino 
acids in the basolateral membrane of the kidney and intestine remains to be identified. 
Cationic amino acids and cystine are taken up across the apical membrane by the 
heteromeric transporter rbat/b0,+AT (SLC3A1/SLC7A9) (reviewed in [25])(Fig. 2). The 
transporter and its role in cystinuria have been reviewed extensively in the past [26,27]. 
Release of cationic amino acids across the basolateral membrane is mediated by the 
heteromeric amino acid transporter 4F2hc/y+LAT1 (Slc3a2/Slc7a7) [25]. Mutations in y+LAT1 
cause lysinuric protein intolerance (LPI), a multisystemic disorder, affecting lung, liver and 
renal epithelial cells. The reader is referred to a recent review discussing the 
pathophysiological mechanisms of LPI [28]. Transport of anionic amino acids across the 
apical membrane in both kidney and intestine is mediated by the glutamate/aspartate 
transporter EAAT3 (SLC1A1) [29] (Fig. 2). Mutations in EAAT3 cause dicarboxylic 
aminoaciduria (DA) [30]. Glutamate is intensely metabolised in epithelial cells [31], but 
release of aspartate occurs through the basolateral membrane, the mediator of which 
remains unknown.  
   
Mice lacking the neutral amino acid transporter B0AT1 (SLC6A19). Three mouse models are 
relevant to this transporter. Collectrin-deficient mice lack B0AT1 [8] in the kidney, ACE2-
deficient mice lack B0AT1 in the intestine [32] and B0AT1-deficient mice lack the transporter 
in all tissues without affecting collectrin or ACE2 expression [33]. B0AT1-deficient mice are a 
model of human Hartnup disorder. Hartnup disorder is characterised by highly elevated 
levels of all neutral amino acids in the urine and reduced absorption of neutral amino acids 
in the intestine [7]. Clinically it is a benign disorder in adults, children frequently develop a 
skin rash and in rare cases show cerebellar ataxia. In countries with high quality nutrition 
symptoms are rare. The symptoms of Hartnup disorder are related to pellagra which is 
caused by a lack of niacin (nicotinamide or nicotinic acid). The common cause appears to be 
the reduced synthesis of NAD(P)H for which both tryptophan and niacin are precursors. 
B0AT1-deficient mice show reduced growth and body weight after weaning, particularly in 
males [33]. Histological analysis revealed no obvious abnormalities. High levels of all neutral 
amino acids were found in the urine. In the intestine Na+-dependent uptake of leucine, 
glutamine, tryptophan and histidine was completely abolished. Surprisingly, glucose uptake 
was also reduced by about 50% in animals lacking B0AT1. Peptide uptake was unaffected, 
suggesting that no compensation of the reduced amino acid uptake by way of peptide 
uptake occurred. In the kidney Na+-dependent uptake of leucine and tryptophan was 
completely abolished, while residual transport activity was identified for glutamine, 
histidine, glycine and proline. The residual uptake of proline (40%) had characteristics 
consistent with the expression of SIT1 (Slc6a20a). The residual glycine uptake was most 
likely mediated by B0AT3 (Slc6a18). B0AT1-deficient mice had less body fat than wildtype 
mice and could not maintain body weight on diets with different protein contents. Blood 
glucose levels before and after feeding were normal, but the corresponding insulin release 
was significantly smaller pointing to improved insulin sensitivity. These results are similar to 
those reported for collectrin-deficient mice (see below and [34]). Enterocytes showed signs 
of amino acid starvation as indicated by reduced mTOR activation and upregulation of the 
GCN2 pathway [3]. 
 
Mice lacking angiotensin converting enzyme 2 (ACE2) 
Mice lacking ACE2 have a variety of pathologies, such as impaired cardiac contractility, late-
onset nephrotic glomerulosclerosis, enhanced susceptibility to diabetic kidney injury and 
acute respiratory stress syndrome. These are unrelated to its interaction with amino acid 
transporters and the reader is referred to a recent review for further information [35]. Lack 
of ACE2 also generates a physiological phenotype due to the lack of B0AT1 expression in the 
intestine, while reabsorption in the kidney is almost unaffected consistent with the 
dominant expression of collectrin in the proximal tubule [12]. Lack of neutral amino acid 
uptake in the intestine results in reduced plasma concentration of neutral amino acid (10-
25%), particularly of tryptophan (60% reduced) [32]. In the intestine absorption was 
delayed, resulting in elevated amino acid concentrations in the terminal ileum. Urine output 
was increased in aged ACE2-deficient animals, resulting in reduced urine osmolality. The 
urine pH was more acidic. Muscle mass was not reduced in the animals, but may have a 
higher turnover, as observed in collectrin-deficient mice [34]. Similar to B0AT1-deficient 
animals, significant weight loss was observed on a low protein diet, but no pellagra-like 
symptoms were observed. Reduced amino acid uptake in the intestine causes amino acid 
starvation in enterocytes [33]. This results in reduced secretion of antimicrobial peptides 
(defensins), which in turn causes changes to the intestinal microflora and causes intestinal 
inflammation [36]. Infusion of recombinant soluble ACE2 or deletion of the angiotensin 
receptor 1a did not alleviate any of these symptoms, demonstrating that this phenotype of 
ACE2 deficient mice is not related to its role in the local renin-angiotensin system. When 
challenged with dextran-sulphate (DSS), an irritant that disrupts the intestinal epithelial 
barrier and results in colitis, a profoundly increased inflammatory reaction was observed in 
ACE2-deficient mice compared to wildtype mice. Transplantation of bone marrow from 
ACE2-deficient mice to wildtype mice and vice versa did not change the DSS-induced colitis, 
suggesting that the response was not caused by an altered immune cell response due to lack 
of ACE2. Consistent with the role of ACE2, a protein-free diet also rendered the intestinal 
epithelium highly sensitive to DSS-induced colitis. As pointed out above tryptophan together 
with niacin are the main precursors for the synthesis of NAD(P)H. Pellagra and Hartnup 
disorder are both known to be associated with colitis. Indeed, provision of a tryptophan 
dipeptide, which is transported by the peptide transporter PepT1, thus circumnavigating the 
lack of B0AT1, restored serum tryptophan levels and rescued enhanced DSS susceptibility. 
Cell death of epithelial cells was similar in both ACE2-deficient and wildtype animals. 
However, production of multiple antimicrobial peptides was reduced in ACE2-deficient 
animals, such as alpha-defensins 1,4 and 5. Both B0AT1 and ACE2-deficient animals show 
reduced mTOR activation in the intestine, which in turn could regulate production of 
defensins. Consistent with this notion production of antimicrobial peptides was similarly 
reduced after administration of rapamycin and is also reduced in B0AT1-deficient animals 
(unpublished data). Supplementation of tryptophan dipeptide activated mTOR and 
upregulated production of antimicrobial peptides. These alterations of the intestinal 
homeostasis caused a change of the intestinal microbiome, which also could be reversed by 
administration of tryptophan dipeptide. Transplantation of the ileocaecal gut microbiota 
from ACE2-deficient mice to wild-type mice transmitted the inflammatory phenotype.  
 
Mice lacking collectrin (TMEM27) 
Collectrin-deficient mice are healthy and do not have obvious histological anomalies. The 
initial characterisation showed significant aminoaciduria, similar to Hartnup disorder, but 
there is no intestinal phenotype [8,37]. Collectrin has been shown to be expressed in the 
pancreas where it is localised on insulin-containing vesicles in β-cells [38]. A thorough 
morphometric analysis of pancreas function, however, failed to reveal any changes of β-cell 
numbers, proliferation and islet area and numbers [34]. Insulin secretion was similar in 
wildtype and collectrin-deficient mice in vivo and from isolated islets in vitro. Despite 
normal pancreas morphology and function, collectrin-deficient mice showed improved 
insulin sensitivity as assessed by insulin tolerance tests [34]. Glucose tolerance was similar, 
but required less insulin. Collectrin-deficient animals were slightly smaller. Investigation of 
amino acid metabolism showed a reduction of short-chain acyl-carnitines, which are the 
breakdown products of branched-chain amino acids. Also free carnitine was significantly 
reduced. The study concluded that an increased amount of energy utilisation occurred to 
compensate for the loss of amino acids. Muscle proteolysis appeared to be increased, but 
was balanced by increased protein synthesis, as no loss of muscle mass was observed.     
 
Mice lacking the neutral amino acid transporter B0AT3 (SLC6A18) 
B0AT3-deficient mice are healthy and breed normally. An initial characterisation revealed 
increased urinary excretion of glycine and hypertension [39]. Using mice that were back-
crossed ten generations against the C57BL/6 background confirmed the glycinuria, but also 
found significantly increased fractional excretion of methionine [12]. Other amino acids 
were slightly elevated in the urine increasing the fractional excretion by 5-10%. No 
difference was found in blood pressure between wildtype and B0AT3-deficient mice under 
resting conditions. However, under stress a slightly elevated blood pressure was observed in 
the nullizygous mice. In the human population a stop codon occurs at high frequency in 
SLC6A18, which is not associated with elevated blood pressure [40]. As pointed out above 
PAT2 has replaced B0AT3 in the human kidney and therefore blood pressure changes would 
rather be associated with mutations in PAT2 [18].  
 
Mice lacking the neutral amino acid transporter LAT2 (SLC7A8). LAT2 is mainly expressed in 
the kidney, intestine, brain and testis. No abnormalities were observed in the histology of 
these organs [41]. LAT2-deficient mice have a normal body weight and size. Litter size and 
frequency are normal. Urine amino acid analysis revealed less than two-fold increases for 
serine, threonine, glutamine, leucine, valine and glycine. In vitro experiments in MDCK cells 
suggested a role of LAT2 in cysteine export [42]. Cysteine concentration, however, was 
reduced in the urine. Overall the results suggest a modulatory role of LAT2 in amino acid 
reabsorption. The results confirm in vitro experiments showing LAT2 to be an obligatory 
exchanger, not capable of mediating net flux of amino acids across the basolateral 
membrane. Notably, there was no increase of aromatic amino acids in the urine suggesting 
that these are transported by a separate transporter (TAT1, see below). In the blood plasma 
increased concentrations of the neutral amino acids glycine, alanine, serine, threonine, 
glutamine and valine were observed. Since the same amino acids showed an increased loss 
in the urine, the results suggest some changes to the absorption of these amino acids in the 
intestine or altered metabolism due to the lack of LAT2. In addition levels of aspartate and 
lysine were elevated, also pointing to altered absorption in the intestine.  
 
Mice lacking the aromatic amino acid transporter TAT1 (SLC16A10) 
TAT1 has an overlapping distribution with LAT2 in the intestine and kidney. In addition it is 
found in perivenous hepatocytes, muscle and brain [43].  In epithelial cells TAT1 is expressed 
in the basolateral membrane where it is thought to mediate the net export of aromatic 
amino acids after uptake across the apical membrane in both kidney and intestine. TAT1-
deficient mice grow and breed normally and do not have histological changes in organs 
expressing TAT1 [44]. There was no compensatory upregulation of other transporters in 
various organs. Plasma concentration of aromatic amino acids were elevated (Phe, ~2x, Trp 
~3x, Phe ~8x) in TAT1-deficient animals compared to wildtype animals. Most others were 
slightly reduced (gly, ala, met, ser, thr, pro, asn, gln,lys, arg). Feeding a high protein diet 
increased the concentration of branched-chain amino acids in the plasma of wildtype and 
TAT1-deficient mice, but had little effect on other amino acids. Urine volume was increased 
in TAT1-deficient mice on normal and high-protein diet. With the exception of glycine, 
proline and glutamine urine amino acid excretion was minimal in wildtype mice (<500 
µmol/24h) on both normal diet (nd) and high-protein diet (hpd). TAT1-deficient mice, by 
contrast, showed a dramatic increase of tyrosine excretion (50x nd; 64x hpd) and of 
tryptophan (6x nd; 95x hpd). Phenylalanine excretion was less pronounced (2x nd; 9x hpd). 
On the high-protein diet amino acid excretion of LAT2 substrates val, leu, ile, ser, thr, gln 
and his was also increased 3-7 fold, suggesting that recycling of aromatic amino acids could 
contribute to neutral amino acid reabsorption at a high load by being exchange substrates 
for LAT2.    
 
Conclusion: 
Mouse models of epithelial neutral amino acid transporters reveal a significant impact on 
amino acid homeostasis. These are caused both by reduced intestinal absorption and loss in 
the kidneys. Purely renal phenotypes are usually less severe than the phenotype caused by 
lack of the intestinal transport activity. A consistent picture has emerged how epithelial 
transport of neutral amino acids is mediated. The impact on whole body amino acid 
homeostasis is still only partially understood.  
 
Key points: 
• B0AT1(SLC6A19) plays an important role for whole body amino acid homeostasis and 
also in the control of the intestinal microflora, a key metabolite for many of the 
observed symptoms due to lack of B0AT1 appears to be tryptophan. 
• Renal and intestinal phenotypes due to lack of B0AT1 can be separated using 
collectrin- or ACE2-deficient mice.  
• The main efflux protein in the basolateral membrane remains elusive, while the 
4F2hc/LAT2 (SLC3A2/SLC7A8) heteromeric transporter has a modulatory role in 
amino acid absorption. 
• B0AT3(SLC6A18) mediates glycine absorption in mice but not in humans, its 
involvement in blood pressure regulation remains unclear. 
• TAT1 (SLC6A18) serves to mediate epithelial transport of aromatic amino acids. 
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Figure 1: Organisation of neutral amino acid transport in epithelial cells. 
Transporters are indicated by the name of the cloned transporter and also the corresponding 
transport activity (within circles). Sections of the proximal tubule are indicated on the right. 
Abbreviations: AA0, neutral amino acids; P, proline; G, glycine. 
 
Figure 2: Organisation of cationic and anionic amino acid transport in epithelial cells. 
Transporters are indicated by the name of the cloned transporter and also the corresponding 
transport activity (within circles). Sections of the proximal tubule are indicated on the right. 
Abbreviations: AA0, neutral amino acids; AA+, cationic amino acids; AA-, anionic amino 
acids; C-, cysteine; G, glycine. 
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